Skip to content

Study · Randomized controlled trial · n = 102 · 1989

3 results

[Comparison of the antiemetic effectiveness of high-dose corticosteroids with synacthene in nausea induced by chemotherapy: results of a randomized study].

Brice P, Fiere D, Gastaut JL, Simon-Lejeune C, Carcassonne Y, Tredaniel J, Lenoble M, Gisselbrecht C

Bulletin du cancer1 Jan 1989Cited by 3 (Europe PMC)

PMID2775883 (opens in a new tab)PepBankPUB-02775883
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In chemotherapy patients, no nausea occurred in 37% with tetracosactide versus 40% with methylprednisolone, with similar results.

    In plain wordsIn chemotherapy patients, tetracosactide and methylprednisolone gave similar rates of no nausea.

    Peptide
    Cosyntropin
    Outcome
    Direction not reportedAbsence of nausea
    Study

    n = 102

    Comparator
    Methylprednisolone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg on D1 and 2 mg/d on D2 and D3 · 3 daysAs given in this study (human).

    Measurements

    No nausea
    37%
    tetracosactide
    No nausea
    40%
    methylprednisolone

    Source sentences

    Summary
    Results were similar in both groups, respectively for tetracosactide and methylprednisolone: no nausea 37 versus 40%, less than 3 emesis 69% versus 73%.
    1 context sentence
    Summary · context
    One hundred two patients submitted to intensive chemotherapy were included in a randomized study with cross over comparing for the second course two anti-emetics: tetracosactide (D1: 3 mg, D2 and D3: 2 mg/d) and methylprednisolone (D1: 240 mg, D2 and D3: 160 mg/d). Most patients presented with malignant lymphoma.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In chemotherapy patients, fewer than 3 emesis episodes occurred in 69% with tetracosactide versus 73% with methylprednisolone, with similar results.

    In plain wordsIn chemotherapy patients, tetracosactide and methylprednisolone gave similar rates of fewer than three vomiting episodes.

    Peptide
    Cosyntropin
    Outcome
    Direction not reportedFewer than three emesis episodes
    Study

    n = 102

    Comparator
    Methylprednisolone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg on D1 and 2 mg/d on D2 and D3 · 3 daysAs given in this study (human).

    Measurements

    Fewer than 3 emesis episodes
    69%
    tetracosactide
    Fewer than 3 emesis episodes
    73%
    methylprednisolone

    Source sentences

    Summary
    Results were similar in both groups, respectively for tetracosactide and methylprednisolone: no nausea 37 versus 40%, less than 3 emesis 69% versus 73%.
    1 context sentence
    Summary · context
    One hundred two patients submitted to intensive chemotherapy were included in a randomized study with cross over comparing for the second course two anti-emetics: tetracosactide (D1: 3 mg, D2 and D3: 2 mg/d) and methylprednisolone (D1: 240 mg, D2 and D3: 160 mg/d). Most patients presented with malignant lymphoma.
  3. 03HumanRandomized controlled trialSafety outcome

    In chemotherapy patients, secondary effects were observed in 5% with tetracosactide and 8% with methylprednisolone, with no significance stated.

    In plain wordsIn chemotherapy patients, secondary effects occurred in 5% with tetracosactide and 8% with methylprednisolone, with no significance stated.

    Peptide
    Cosyntropin
    Outcome
    Direction not reportedSecondary effects
    Study

    n = 102

    Comparator
    Methylprednisolone
    Outcome group
    Adverse events · Whole body
    Studied dose
    3 mg on D1 and 2 mg/d on D2 and D3 · 3 daysAs given in this study (human).

    Measurements

    Secondary effects
    5%
    tetracosactide
    Secondary effects
    8%
    methylprednisolone

    Source sentences

    Summary
    Secondary effects were observed in 5 and 8% of cases.
    2 context sentences
    Summary · context
    Results were similar in both groups, respectively for tetracosactide and methylprednisolone: no nausea 37 versus 40%, less than 3 emesis 69% versus 73%.
    Summary · context
    One hundred two patients submitted to intensive chemotherapy were included in a randomized study with cross over comparing for the second course two anti-emetics: tetracosactide (D1: 3 mg, D2 and D3: 2 mg/d) and methylprednisolone (D1: 240 mg, D2 and D3: 160 mg/d). Most patients presented with malignant lymphoma.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.